$11.450
+0.633 (+5.53%)收盘时
TLX 同业对比
In the context of the broader market, TLX competes directly with industry leaders such as CRSP and DNTH. With a market capitalization of $3.84B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of N/A stands against CRSP's 100.00% and DNTH's 100.00%. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.
Telix Pharmaceuticals Ltd 财务表现
Telix reported a revenue of $247 million for Q2 2026, a 21% increase year-over-year, and expects to exceed $1 billion in revenue for the full year 2026, indicating strong growth potential.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。